Ketamine for PTSD Treatment

Reviewed and authored by Dr. David Mahjoubi, MD — Board-Certified Anesthesiologist, President of the American Board of Ketamine Physicians (ABKP), Founder of NutraBrain Clinic. Practicing ketamine medicine since 2014. Author of The Art & Science of Ketamine Medicine.

PTSD is one of the most difficult conditions in modern psychiatry to treat. Standard pharmacological options — SSRIs, SNRIs, and benzodiazepines — provide partial benefit for some patients, no benefit for many, and side effects that limit adherence for nearly everyone. Trauma-focused therapies (EMDR, prolonged exposure, CPT) are effective for some but require deep engagement with traumatic memory, which many patients can’t tolerate without preliminary relief from baseline arousal. This is where ketamine has emerged as one of the most promising treatments in 25 years.

Why conventional PTSD treatments often fall short

PTSD is fundamentally a disorder of stuck memory — traumatic experiences encoded in a way that the body and brain replay them as if they’re still happening. The amygdala (threat detection) stays on high alert. The hippocampus (memory contextualization) underperforms. The prefrontal cortex (executive regulation) loses the ability to override the threat response. The only FDA-approved drugs for PTSD — sertraline (Zoloft) and paroxetine (Paxil) — modestly dampen hyperarousal in some patients but don’t “unstick” the trauma memory. Roughly 40–60% of patients see no meaningful benefit, and side effects (sexual dysfunction, emotional blunting, sleep disruption) drive many to discontinue.

How ketamine works on the trauma circuit

Ketamine blocks NMDA receptors, which triggers rapid glutamate release and a downstream surge in brain-derived neurotrophic factor (BDNF) and synaptogenesis (formation of new neural connections). The clinical effect: within hours of dosing, patients enter a brief window of heightened neuroplasticity lasting 24–72 hours. During this window the amygdala becomes less reactive to trauma cues, the prefrontal cortex regains inhibitory control over fear responses, and traumatic memories become more “movable” — they can be re-examined without overwhelming arousal. This is fundamentally different from SSRIs. SSRIs slowly turn down the volume on the alarm. Ketamine creates a window during which the alarm circuitry can be rewired.

The clinical evidence

Feder et al. (2014, JAMA Psychiatry) demonstrated that a single IV ketamine dose produced rapid, significant PTSD symptom reduction versus midazolam control. Feder et al. (2021, American Journal of Psychiatry) showed that six IV infusions over two weeks produced significant, sustained improvement in chronic PTSD with response rates around 67%. Multiple naturalistic studies of repeated IV and intranasal ketamine show 30–50% symptom reductions on standardized PTSD scales (CAPS-5, PCL-5). Combination protocols pairing ketamine with trauma-focused therapy (KAP — ketamine-assisted psychotherapy) show promising outcomes for treatment-resistant PTSD. The evidence base is strongest for IV protocols, but observational data on intranasal and sublingual at-home administration shows comparable benefit in many patients when combined with appropriate clinical support.

The NutraBrain protocol for PTSD

Slower-onset, longer-arc dosing. For PTSD I typically prescribe sublingual troches rather than nasal spray. The longer therapeutic window (60–90 minutes of peak effect) provides more time for emotional processing during the session.

Lower starting doses. PTSD patients are often hyper-responsive to dissociation. Starting at the lower end of the therapeutic range (50–75 mg sublingually) prevents destabilization.

Spacing matched to processing capacity. Initial sessions typically spaced 5–7 days apart to allow integration. Stacking too quickly leads to “ketamine fatigue” without therapeutic benefit.

Strong encouragement to pair with therapy. Ketamine creates the window; therapy does the work inside it. I strongly encourage PTSD patients to maintain a relationship with a trauma-informed therapist (EMDR, IFS, somatic experiencing, or KAP-trained) during treatment.

Optional oxytocin pairing. For patients whose PTSD involves attachment trauma, relational disconnection, or emotional numbness, the exclusive NutraBrain ketamine + oxytocin formulation is often the right choice.

What patients typically experience

The first session usually produces noticeable shifts in: intensity of intrusive memories (many describe them feeling “smaller” or “further away”), sleep (fewer nightmares, longer duration), startle response and hypervigilance (often reduced within 24–72 hours), and emotional accessibility (patients who have been emotionally numb often describe being able to feel again). Many describe the first session as the first time in years they could remember the trauma without re-living it. That separation between memory and re-experiencing is the central therapeutic shift. By 4–6 sessions, many patients see significant reduction on PTSD severity measures.

Who is and isn’t a candidate

Strong candidates: treatment-resistant PTSD where SSRIs or therapy alone haven’t worked; veterans, first responders, and trauma survivors with chronic PTSD; PTSD with comorbid depression or anxiety; patients who can’t tolerate trauma-focused therapy without preliminary symptom relief; patients with relational/attachment trauma.

Not appropriate for at-home ketamine: dissociative identity disorder or other severe dissociative disorders; active psychosis or untreated bipolar disorder; recent (within 6 months) substance use disorder without stable recovery; patients who cannot ensure a safe, private environment; patients without any ongoing mental health support during treatment.

Frequently asked questions

If you’re considering ketamine for PTSD

You don’t need to keep cycling through SSRIs, suffer through medication side effects, or put off therapy because the arousal feels too intense to enter. Ketamine, used properly with the right physician oversight and integration support, can change what’s possible. Take the 20-second qualifying quiz or schedule a consultation. NutraBrain operates across 13 states with 100% telehealth.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Ketamine therapy is a prescription treatment and should only be undertaken under physician supervision. Individual outcomes vary. Ketamine use for mental health and chronic pain conditions outside of FDA-approved esketamine (Spravato) is considered off-label. Speak with a qualified physician about whether ketamine therapy is appropriate for you.

Last reviewed: June 2026